NewAmsterdam Pharma Co N.V (NAMS) Cash & Equivalents: 2022-2025
Historic Cash & Equivalents for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $538.4 million.
- NewAmsterdam Pharma Co N.V's Cash & Equivalents rose 27.36% to $538.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $538.4 million, marking a year-over-year increase of 27.36%. This contributed to the annual value of $771.7 million for FY2024, which is 126.68% up from last year.
- Per NewAmsterdam Pharma Co N.V's latest filing, its Cash & Equivalents stood at $538.4 million for Q3 2025, which was down 4.51% from $563.9 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma Co N.V's Cash & Equivalents ranged from a high of $771.7 million in Q4 2024 and a low of $340.4 million during Q4 2023.
- For the 3-year period, NewAmsterdam Pharma Co N.V's Cash & Equivalents averaged around $502.2 million, with its median value being $441.3 million (2023).
- In the last 5 years, NewAmsterdam Pharma Co N.V's Cash & Equivalents fell by 27.21% in 2023 and then surged by 126.68% in 2024.
- NewAmsterdam Pharma Co N.V's Cash & Equivalents (Quarterly) stood at $467.7 million in 2022, then decreased by 27.21% to $340.4 million in 2023, then surged by 126.68% to $771.7 million in 2024, then climbed by 27.36% to $538.4 million in 2025.
- Its Cash & Equivalents stands at $538.4 million for Q3 2025, versus $563.9 million for Q2 2025 and $748.4 million for Q1 2025.